These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22280200)

  • 21. Quality-adjusted life-years, comparative effectiveness in cancer care, and measuring outcomes in the underserved.
    Kilbridge KL
    Oncology (Williston Park); 2010 May; 24(6):530-6. PubMed ID: 20568594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health related utility measurement: an introduction.
    Bakker C; van der Linden S
    J Rheumatol; 1995 Jun; 22(6):1197-9. PubMed ID: 7674256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality-adjusted life years.
    Bravo Vergel Y; Sculpher M
    Pract Neurol; 2008 Jun; 8(3):175-82. PubMed ID: 18502950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
    Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
    Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The future of outcomes measurement in rheumatology.
    Kaplan RM
    Am J Manag Care; 2007 Dec; 13 Suppl 9():S252-5. PubMed ID: 18095788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding quality-adjusted life years and their application to pharmacoeconomic research.
    Raisch DW
    Ann Pharmacother; 2000; 34(7-8):906-14. PubMed ID: 10928403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years.
    Campbell JD; Zerzan J; Garrison LP; Libby AM
    Clin Ther; 2013 Apr; 35(4):364-70. PubMed ID: 23477685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Converting condition-specific measures into preference-based outcomes for use in economic evaluation.
    Petrillo J; Cairns J
    Expert Rev Pharmacoecon Outcomes Res; 2008 Oct; 8(5):453-61. PubMed ID: 20528330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using time trade-off methods to assess preferences over health care delivery options: a feasibility study.
    Guo J; Konetzka RT; Dale W
    Value Health; 2014 Mar; 17(2):302-5. PubMed ID: 24636391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated current health time-trade-off assessments in women's health.
    Tosteson AN; Kneeland TS; Nease RF; Sumner W
    Value Health; 2002; 5(2):98-105. PubMed ID: 11918825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matching study designs to disability-related comparative effectiveness research questions.
    Ballou J; Rich E; Kehn M
    J Comp Eff Res; 2013 Jan; 2(1):59-68. PubMed ID: 24236522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ordinal preference elicitation methods in health economics and health services research: using discrete choice experiments and ranking methods.
    Ali S; Ronaldson S
    Br Med Bull; 2012 Sep; 103(1):21-44. PubMed ID: 22859714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature.
    Thorrington D; Eames K
    PLoS One; 2015; 10(8):e0135672. PubMed ID: 26275302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are methods for estimating QALYs in cost-effectiveness analyses improving?
    Neumann PJ; Zinner DE; Wright JC
    Med Decis Making; 1997; 17(4):402-8. PubMed ID: 9343798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health related utility measurement in rheumatology: an introduction.
    Bakker CH; Rutten-van Mölken M; van Doorslaer E; Bennett K; van der Linden S
    Patient Educ Couns; 1993 May; 20(2-3):145-52. PubMed ID: 8337191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Controversies around QALYs].
    Rogalewicz V; Barták M
    Vnitr Lek; 2017; 63(4):242-248. PubMed ID: 28520447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating interventions in health: a reconciliatory approach.
    Wolff J; Edwards S; Richmond S; Orr S; Rees G
    Bioethics; 2012 Nov; 26(9):455-63. PubMed ID: 21535065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations.
    Matza LS; Stewart KD; Lloyd AJ; Rowen D; Brazier JE
    Value Health; 2021 Jun; 24(6):812-821. PubMed ID: 34119079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.
    Wailoo A; Tsuchiya A; McCabe C
    Pharmacoeconomics; 2009; 27(12):983-9. PubMed ID: 19908923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.
    Rowen D; Brazier J; Ara R; Azzabi Zouraq I
    Pharmacoeconomics; 2017 Dec; 35(Suppl 1):33-41. PubMed ID: 29052164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.